The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing nab-paclitaxel plus carboplatin (nab-PC) with solvent-based paclitaxel plus carboplatin (sb-PC) in first-line advanced non-small cell lung cancer (NSCLC).
Corey J. Langer
Consultant or Advisory Role - Celgene
Vera Hirsh
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Yin Wan
Research Funding - Celgene
Fang-Ju Lin
Research Funding - Celgene
Scott Whiting
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Research Funding - Celgene
Teng Jin Ong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Marc Botteman
Research Funding - Celgene